



## Elaprase (idursulfase)

Effective Date: January 1, 2021

Number: MG.MM.PH.308

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definitions

Elaprase is human iduronate-2-sulfatase (idursulfase), produced in a human cell line using recombinant DNA technology. Idursulfase hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from dermatan and heparin sulfate in lysosomes of various cell types. Elaprase is indicated for patients with Hunter syndrome (Mucopolysaccharidosis type II [MPS II]). Elaprase has been shown to improve walking capacity in patients  $\geq 5$  years of age. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long-term clinical outcome; however, treatment has reduced spleen volume similar to that of patients  $\geq 5$  years of age.

### Dosing

Each dose must not exceed 0.5 mg/kg administered intravenously no more frequently than once a week.

### Length of Coverage

- Approvals will be granted for 12 months

### Guideline

#### Mucopolysaccharidosis Type II (Hunter Syndrome)

- The diagnosis is established by one of the following:

- Patient has a laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum, or plasma; **OR**
- Patient has a molecular genetic test demonstrating iduronate-2-sulfatase gene mutation; **AND**
- Elaprase is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

#### Limitations/Exclusions

- Coverage is not recommended for circumstances not listed in the Guideline. Criteria will be updated as new published data are available.

#### Applicable Procedure Codes

J1743	Injection, idursulfase, 1 mg; 1 mg = 1 billable unit
-------	--

#### Applicable NDC Codes

54092-0700-xx	Elaprase 6 mg/3 mL single-use vial for injection
---------------	--

#### Applicable Diagnosis Codes

E76.1	Mucopolysaccharidosis, type II
-------	--------------------------------

#### Revisions

1/1/2021	Criteria apply to Commercial, Medicare, and Medicaid members.
----------	---

#### REFERENCES

1. Elaprase® injection for intravenous use [prescribing information]. Lexington, MA: Shire Human Genetic Therapies, Inc.; November, 2018.
2. Scarpa M, Almassy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. *Orphanet J Rare Dis.* 2011;6:72.
3. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. *Pediatrics.* 2009;124:e1228-e1239.
4. Giugliani R, Federhen A, Munoz Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. *Genet Mol Biol.* 2010;33:589-604.
5. D'Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: One hundred years of research, diagnosis, and treatment. *Int J Mol Sci.* 2020;21:E1258.